EP
Eversept Partners Portfolio holdings
AUM
$992M
This Quarter Return
+3.05%
1 Year Return
+2.54%
3 Year Return
+103.47%
5 Year Return
+181.01%
10 Year Return
–
AUM
$1.25B
AUM Growth
+$1.25B
(+15%)
Cap. Flow
+$156M
Cap. Flow
% of AUM
12.52%
Top 10 Holdings %
Top 10 Hldgs %
49.35%
Holding
117
New
34
Increased
30
Reduced
22
Closed
15
Top Buys
| 1 |
Labcorp
LH
|
$36.1M |
| 2 |
Ascendis Pharma
ASND
|
$32.4M |
| 3 |
Community Health Systems
CYH
|
$25.3M |
| 4 |
CTLT
CATALENT, INC.
CTLT
|
$24.5M |
| 5 |
Icon
ICLR
|
$18.8M |
Top Sells
| 1 |
Qiagen
QGEN
|
$26.2M |
| 2 |
AMRN
Amarin Corp
AMRN
|
$25.8M |
| 3 |
Organon & Co
OGN
|
$21.2M |
| 4 |
Danaher
DHR
|
$17.3M |
| 5 |
AMN Healthcare
AMN
|
$17.1M |
Sector Composition
| 1 | Healthcare | 93.33% |
| 2 | Industrials | 1.35% |
| 3 | Financials | 0.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
United Therapeutics
UTHR
$13.8B
| $82M | 5.67% | 444,471 +1,526 | +0.3% | +$282K |
|
|
2
Ascendis Pharma
ASND
$11.8B
| $71M | 4.91% | 445,203 +203,429 | +84% | +$32.4M |
|
|
3
Community Health Systems
CYH
$387M
| $70.1M | 4.85% | 5,988,163 +2,166,434 | +57% | +$25.3M |
|
|
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $69.5M | 4.81% | 634,670 -32,068 | -5% | -$3.51M |
|
|
XLRN
5
DELISTED
Acceleron Pharma Inc.
XLRN
| $60.1M | 4.16% | 349,494 +14,449 | +4% | +$2.49M |
|
|
AMRN
6
Amarin Corp
AMRN
$311M
| $59.2M | 4.09% | 11,604,990 -5,064,481 | -30% | -$25.8M |
|
7
AstraZeneca
AZN
$248B
| $53.5M | 3.7% | 890,808 -94,914 | -10% | -$5.7M |
|
8
Avantor
AVTR
$9.18B
| $52.8M | 3.65% | 1,292,014 +317,377 | +33% | +$13M |
|
9
ARK Genomic Revolution ETF
ARKG
$1.04B
| $51.5M | 3.56% | 689,501 -83,979 | -11% | -$6.27M |
|
|
10
Danaher
DHR
$147B
| $45.1M | 3.12% | 147,938 -56,767 | -28% | -$17.3M |
|
11
Amneal Pharmaceuticals
AMRX
$3B
| $36.6M | 2.53% | 6,849,834 +1,225,109 | +22% | +$6.54M |
|
|
12
Labcorp
LH
$23.1B
| $36.1M | 2.5% | +128,311 | New | +$36.1M |
|
13
Teva Pharmaceuticals
TEVA
$21.1B
| $34.6M | 2.39% | 3,554,804 -249,601 | -7% | -$2.43M |
|
14
Envista
NVST
$3.52B
| $33.9M | 2.34% | 810,881 +154,783 | +24% | +$6.47M |
|
15
McKesson
MCK
$85.4B
| $32.3M | 2.23% | 161,708 +86,708 | +116% | +$17.3M |
|
16
Bristol-Myers Squibb
BMY
$96B
| $27.8M | 1.92% | 464,801 -13,527 | -3% | -$809K |
|
|
CTLT
17
DELISTED
CATALENT, INC.
CTLT
| $24.5M | 1.7% | +184,299 | New | +$24.5M |
|
|
18
Icon
ICLR
$13.8B
| $18.8M | 1.3% | +71,911 | New | +$18.8M |
|
19
Masimo
MASI
$7.59B
| $18.1M | 1.25% | +67,000 | New | +$18.1M |
|
|
OCDX
20
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
| $16.9M | 1.17% | 914,986 -479,298 | -34% | -$8.86M |
|
|
RCM
21
DELISTED
R1 RCM Inc. Common Stock
RCM
| $16.8M | 1.16% | 764,780 -5,220 | -0.7% | -$115K |
|
22
Maravai LifeSciences
MRVI
$350M
| $16.1M | 1.11% | 327,810 +252,810 | +337% | +$12.4M |
|
23
Fate Therapeutics
FATE
$120M
| $15.5M | 1.07% | 260,895 -85,452 | -25% | -$5.06M |
|
24
GSK
GSK
$79.9B
| $15.4M | 1.07% | 401,654 +288,975 | +256% | +$11.1M |
|
25
Ionis Pharmaceuticals
IONS
$6.79B
| $15.1M | 1.05% | 450,501 +8,501 | +2% | +$285K |
|